REFERENCES
1. Pingitore P, Romeo S. The role of PNPLA3 in health and disease. Biochim Biophys Acta Mol Cell Biol Lipids 2019;1864:900-6.
2. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 2018;68:268-79.
3. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-5.
4. Anstee QM, Darlay R, Cockell S, et al. EPoS Consortium Investigators. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J Hepatol 2020;73:505-15.
5. Oniki K, Saruwatari J, Izuka T, et al. Influence of the PNPLA3 rs738409 polymorphism on non-alcoholic fatty liver disease and renal function among normal weight subjects. PLoS One 2015;10:e0132640.
6. Musso G, Cassader M, Gambino R. PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease. Hepatology 2015;62:658-9.
7. Mantovani A, Zusi C, Sani E, et al. Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease. Diabetes Metab 2019;45:480-7.
8. Targher G, Mantovani A, Alisi A, et al. Relationship between PNPLA3 rs738409 polymorphism and decreased kidney function in children with NAFLD. Hepatology 2019;70:142-53.
9. Marzuillo P, Di Sessa A, Guarino S, et al. Nonalcoholic fatty liver disease and eGFR levels could be linked by the PNPLA3 I148M polymorphism in children with obesity. Pediatr Obes 2019;14:e12539.
10. Sun DQ, Zheng KI, Xu G, et al. PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. Liver Int 2020;40:107-19.
11. Mantovani A, Taliento A, Zusi C, et al. PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: clinical and experimental findings. Liver Int 2020;40:1130-41.
12. Mantovani A, Zusi C, Csermely A, et al. Association between PNPLA3 rs738409 variant and 5-year estimated glomerular filtration rate decline in post-menopausal women with type 2 diabetes: A panel-data analysis. Nutr Metab Cardiovasc Dis 2023;33:1093-7.
13. Mantovani A, Pelusi S, Margarita S, et al. Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle-aged individuals with metabolic dysfunction. Aliment Pharmacol Ther 2023;57:1093-102.
14. Liu J, Qi W, Wang S, et al. Metabolic disorders induced by PNPLA3 and TM6SF2 gene variants affect chronic kidney disease in patients infected with non-genotype 3 hepatitis C virus. Lipids Health Dis 2023;22:91.
15. Koo BK, An JN, Joo SK, et al. Association between a polymorphism in MBOAT7 and chronic kidney disease in patients with biopsy-confirmed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2020;18:2837-9.e2.
16. Baratta F, D'Erasmo L, Di Costanzo A, et al. Metabolic syndrome but not fatty liver-associated genetic variants correlates with glomerular renal function decline in patients with non-alcoholic fatty liver disease. Biomedicines 2022;10:720.
17. Di Costanzo A, Pacifico L, D'Erasmo L, et al. Nonalcoholic fatty liver disease (NAFLD), but not its susceptibility gene variants, influences the decrease of kidney function in overweight/obese children. Int J Mol Sci 2019;20:4444.
18. Khan A, Turchin MC, Patki A, et al. Genome-wide polygenic score to predict chronic kidney disease across ancestries. Nat Med 2022;28:1412-20.
19. Sun DQ, Targher G, Byrne CD, et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. Hepatobiliary Surg Nutr 2023;12:386-403.
20. Barata L, Feitosa MF, Bielak LF, et al. Insulin resistance exacerbates genetic predisposition to nonalcoholic fatty liver disease in individuals without diabetes. Hepatol Commun 2019;3:894-907.
21. Mallela SK, Patel DM, Ducasa GM, Merscher S, Fornoni A, Al-ali H. Detection and Quantification of Lipid Droplets in Differentiated Human Podocytes. Methods Mol Biol 2019;1996:199-296.
22. Mantovani A, Zusi C, Dalbeni A, Grani G, Buzzetti E. Risk of kidney dysfunction in nafld. Curr Pharm Des 2020;26:1045-61.
23. Wang TY, Wang RF, Bu ZY, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol 2022;18:259-68.
24. Pirola CJ, Sookoian S. Editorial: NAFLD, chronic kidney disease, and pleiotropy-why is PNPLA3 omnipresent? Aliment Pharmacol Ther 2023;57:1180-2.
25. Lonardo A, Mantovani A, Targher G, Baffy G. Nonalcoholic fatty liver disease and chronic kidney disease: epidemiology, pathogenesis, and clinical and research implications. Int J Mol Sci 2022;23:13320.
26. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut 2022;71:156-62.
27. Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol 2017;13:297-310.
